ABBOTT PARK, Ill. and ACTON,
Mass., Feb. 19, 2020
/PRNewswire/ -- Abbott (NYSE: ABT) and Insulet Corporation
(NASDAQ: PODD), the global leader in tubeless insulin pump
technology with its Omnipod® Insulin Management System
(Omnipod System), announced today they are partnering to integrate
Abbott's world-leading1 glucose sensing technology with
Insulet's next-generation tubeless system, the Omnipod Horizon™
Automated Insulin Delivery (AID) System (Omnipod Horizon System),
to offer personalized automated insulin delivery and care for
people living with diabetes.
Controlled through an app on a user's personal smartphone device
– a unique feature that will be offered with the Omnipod Horizon
System – the integrated platform will consist of the trusted
tubeless insulin delivery Pod and Abbott's next-generation
FreeStyle Libre sensor. Through a simple, intuitive design, glucose
data from the sensor will be sent directly to the Pod that is
embedded with an algorithm to automatically adjust insulin delivery
– without the need for an additional device, connection or tubing.
This integrated system will be designed to always remain in
automated insulin delivery mode and can be controlled through an
app on a user's personal smartphone to manually take a dose of
fast-acting insulin, or bolus, before meals for optimal
performance. Additionally, the integrated platform is expected to
be the first combined system with a fully disposable wearable
sensor and pump.
"Abbott is focused on creating future-forward health
technologies that simplify how people living with diabetes manage
their condition so they can live their best lives," said
Jared Watkin, senior vice president,
Diabetes Care, Abbott. "As diabetes care becomes more
interoperable, we're developing more connected approaches to
improve care. Through this partnership, Abbott and Insulet will
offer an integrated digital health platform that is simple and
accurate and will provide a best-in-class user experience."
"We are excited to expand our partnership with Abbott by
building on our consumer-centric Omnipod Horizon platform, which
offers unparalleled simplicity, accuracy, and now sensor choice for
consumers," said Shacey Petrovic,
President and Chief Executive Officer, Insulet. "As
interoperability becomes increasingly important, our approach to
automated insulin delivery will change the future of blood glucose
management by offering consumers greater choice in algorithms,
sensors and overall experience. This collaboration furthers our
shared vision to help our consumers put diabetes in the background,
so they have more freedom to enjoy life."
This connected care solution will integrate both the Omnipod
Horizon System and FreeStyle Libre sensor data, offering a seamless
option that will fit easily into the lives of people with diabetes.
With both Insulet's and Abbott's ability to sell its products
through the pharmacy, users of the integrated platform will benefit
from ease of obtaining supplies with an innovative pay-as-you-go
model.
ABBOTT'S AND INSULET'S NEXT-GENERATION
TECHNOLOGIES
The FreeStyle Libre 2 system, Abbott's
next-generation continuous glucose monitoring (CGM) technology, is
currently approved in Europe2 and offers enhanced
accuracy and optional glucose alarms at no additional cost from the
first-generation FreeStyle Libre system. The FreeStyle Libre 2
system can continuously stream up-to-the-minute glucose data to
digitally connected devices. When used as a standalone system,
users scan the sensor worn on the back of the upper arm for 14 days
to see real-time glucose levels every minute, historical trends and
patterns, and arrows showing where glucose levels are going without
having to fingerstick.3
Expanding upon the current Omnipod DASH Insulin Management
System, Insulet has developed and is currently in clinical trials
for its Omnipod Horizon™ AID System. The intended design of the
technology is to leverage glucose values from a CGM to predict
future glucose values and adjust insulin delivery. The Horizon
System will leverage the technology of the DASH Insulin Management
System on a user's personal smartphone.4
About the Omnipod DASH System:
Insulet's Omnipod DASH
System was designed to serve as the foundation for the company's
future innovation. Designed with patient discretion and convenience
in mind, the Omnipod DASH is a continuous insulin delivery system
consisting of two simple components: a tubeless, waterproof*,
Bluetooth® wireless technology Pod (pump) that
holds up to 200 units of U-100 insulin** and a modern, color
touch-screen Personal Diabetes Manager (PDM) that controls the Pod.
The Omnipod DASH System has a suite of optional mobile apps for
users, caregivers and healthcare practitioners to help simplify
diabetes management. The Omnipod DASH System, which
received U.S. Food and Drug Administration clearance
in June 2018, is the only DTSec and ISO
27001 certified insulin pump for cyber and information
security and safety.
*The Pod has a waterproof IP28 rating for up to 25 feet for
60 minutes. The PDM is not waterproof.
**Additional
insulins that are indicated for use with the Pod
include: Novolog®, Humalog®,
Admelog®, Apidra® and
FIASP®.
About Insulet Corporation:
Insulet
Corporation (NASDAQ: PODD), headquartered
in Massachusetts, is an innovative medical device company
dedicated to making the lives of people with diabetes and other
conditions easier through the use of its Omnipod product platform.
The Omnipod Insulin Management System provides a unique alternative
to traditional insulin delivery methods. With its simple, wearable
design, the disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its
Pod, by tailoring its Omnipod technology platform for the delivery
of non-insulin subcutaneous drugs across other therapeutic areas.
For more information, please
visit: www.insulet.com and www.omnipod.com.
© 2020 Insulet Corporation. Omnipod, DASH and Horizon are
trademarks or registered trademarks of Insulet Corporation. All
rights reserved.
About the FreeStyle Libre System:
Abbott's FreeStyle
Libre technology, the #1 sensor-based glucose monitoring system
used worldwide,1 reads glucose levels through a sensor
that can be worn on the back of the upper arm for up to 14 days,
eliminating the need for fingersticks.3 The FreeStyle
Libre portfolio has changed the lives of more than two million
people across 46 countries5 and has secured
partial or full reimbursement in 36 countries, including
France, Ireland, Japan, the United
Kingdom, and the U.S. For the U.S., important safety
information:
https://www.freestylelibre.us/safety-information.html
About Abbott:
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
107,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
1 Data on file, Abbott Diabetes Care. Data based on
the number of users worldwide for the FreeStyle Libre system
compared to the number of users for other leading personal use,
sensor-based glucose monitoring systems.
2 FreeStyle Libre 2 system is under FDA review and
not yet commercially available in the
United States.
3 A fingerstick test using a glucometer is required
during times of rapidly changing glucose levels when interstitial
fluid glucose levels may not accurately reflect blood glucose
levels; or if hypoglycemia or impending hypoglycemia is reported by
the system; or when symptoms do not match the system readings.
4 Insulet's Omnipod Horizon™ System is an
investigational device, limited by United States Law to
Investigational Use.
5 Data on file, Abbott Diabetes Care.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/abbott-and-insulet-partner-to-integrate-next-generation-glucose-sensing-and-automated-insulin-delivery-technologies-for-seamless-diabetes-care-301007119.html
SOURCE Abbott